Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SPRB
Strong SellSinkerSpruce Biosciences, Inc. · Healthcare · United States · $175M · Avg Vol: $4M/d
14
StockRankGet insider-trade alerts
Q
24
V
31
M
39
P/E (TTM)
—
ROE
-106.0%
D/E
0.1x
Dividend %
—
COMPANY DESCRIPTION
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 10.1M | 4.9M | 0 | -51.3% | — | — | 88.6M | 162.2% |
| EPS | — | -16.81 | -18.49 | -19.72 | -25.34 | — | -38.43 | -26.61 | 8.17 | — |
| Shares | — | 2.8M | 2.8M | 2.8M | 2.8M | 0.0% | 2.9M | — | — | — |
| Debt | — | 6.3M | 4.6M | 2.8M | 0.7M | -51.2% | 7.7M | — | — | — |
| Equity | — | 68.5M | 76.5M | 28.8M | 42.5M | -14.7% | — | — | — | — |
| Op CF | — | -41.7M | -33.3M | -56.0M | -33.3M | — | -42.6M | — | — | — |
| Inv CF | -79.2M | 23.7M | 55.8M | 0 | — | — | — | — | — | — |
| Fin CF | — | -0.2M | 49.1M | -1.6M | 43.5M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+41.1%
SMA 50SMA 200
Close
$58.47
RSI (14)
58.4
52W High
$240.00
From 52W High
0.2%
SCORE BREAKDOWN
Quality
24
ROIC
-84.9%8.5
ROE
-106.0%8.9
GP/Assets
-43.3%1.6
Op. Margin
0.0%38.1
FCF/Assets
-25.2%16.6
Piotroski
439.0
Int. Cover
-50.0x5.9
D/E Ratio
0.09x63.4
Current Ratio
9.23x86.1
Value
31
P/E (TTM)
—N/A
EV/EBITDA
-2.0x25.0
P/FCF
—N/A
P/B
1.9x64.8
P/S
—N/A
Div Yield
—N/A
Momentum
39
52W High %
24%4.9
RS 6M
-20%39.6
SMA 50/200
0.80x15.9
EPS Rev 4W
+10.7%89.7
EPS Rev 12W
—N/A
EPS Improve
+121%79.1
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$175M
P/E (Forward)
7.1x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SPRB are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SPRB | Spruce Biosciences, Inc.(you) | $175M | 14 | Strong Sell |
| LENZ | LENZ Therapeutics, Inc. | $161M | 14 | Strong Sell |
| OTLK | Outlook Therapeutics, Inc. | $156M | 14 | Strong Sell |
| TNYA | Tenaya Therapeutics, Inc. | $155M | 14 | Strong Sell |
| KRRO | Korro Bio, Inc. | $190M | 16 | Strong Sell |
| PEPG | PepGen Inc. | $213M | 14 | Strong Sell |
| KPTI | Karyopharm Therapeutics Inc. | $168M | 11 | Strong Sell |
| VYGR | Voyager Therapeutics, Inc. | $218M | 14 | Strong Sell |
| ABOS | Acumen Pharmaceuticals, Inc. | $211M | 13 | Strong Sell |
| KROS | Keros Therapeutics, Inc. | $219M | 15 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%